Robeco Institutional Asset Management
KZR

Robeco Institutional Asset Management’s Kezar Life Sciences KZR Stock Holding History

Robeco Institutional Asset Management’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-790
Closed -$68K – 1003
2022
Q3 		$68K Buy
+790
New +$76.8K ﹤0.01% 902

Other funds holding KZR

APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

Robeco Institutional Asset Management's KZR Position: Q4 2022 in Review

Robeco Institutional Asset Management sold out of Kezar Life Sciences (KZR) in Q4 2022, closing a stake of 790 shares — an estimated $68K sold.

Robeco Institutional Asset Management first reported a position in KZR in Q3 2022 and held it in 1 quarter. The position peaked at $68K in Q3 2022. 121 funds tracked by Wall St. Rank hold KZR as of Q4 2022.

  • Robeco Institutional Asset Management reported no remaining Kezar Life Sciences position as of Q4 2022 after selling out during the quarter.
  • Robeco Institutional Asset Management sold 790 Kezar Life Sciences shares in Q4 2022, an estimated $68K.
  • Robeco Institutional Asset Management first reported a position in Kezar Life Sciences in Q3 2022 and held it in 1 quarter.
  • Robeco Institutional Asset Management's Kezar Life Sciences position peaked at $68K in Q3 2022.
  • 121 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q4 2022.

Based on Robeco Institutional Asset Management's 13F filing for Q4 2022, filed 7 Feb 2023.